Elite in Hemolytic Anemia

R Colombatti-Raffaella

Via Gustiniani 1, Padova, 
Padova, IT 
Elite in Hemolytic Anemia
Via Gustiniani 1, Padova, 
Padova, IT 
OverviewLocationsClinical Research

Overview

R Colombatti-Raffaella practices in Padova, Italy. Colombatti-Raffaella is rated as an Elite expert by MediFind in the treatment of Hemolytic Anemia. Their top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 97 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 77 articles and participated in 3 clinical trials in the study of Hemolytic Anemia.

Locations

Via Gustiniani 1, Padova, Padova, Italy
Other Locations
Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Enrollment Status: Terminated
Publish Date: June 13, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2024
Intervention Type: Drug
View 2 Less Clinical Trials

97 Total Publications

Metabolomics in sickle cell disease: Current knowledge and gaps - A scoping review.
Metabolomics in sickle cell disease: Current knowledge and gaps - A scoping review.
Journal: Blood reviews
Published: June 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Colombatti-Raffaella's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile